Klaus Krueger

Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial

Frank Buttgereit, G Doering, Achim Schaeffler et al. · The Lancet · 2008 · 396 citations

Medicine, Pharmacotherapy, Musculoskeletal Medicine +11

Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis

Frank Buttgereit, Stanisław Sierakowski, Erika Gromnica‐Ihle et al. · Annals of the Rheumatic Diseases · 2010 · 109 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment

Jürgen Rech, Axel J. Hueber, Stephanie Finzel et al. · Annals of the Rheumatic Diseases · 2015 · 95 citations · Full text

Life Sciences, Immunology, Internal Medicine +17

Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon-γ release assays under real-life conditions

Stefan Kleinert, H-P Tony, Klaus Krueger et al. · Annals of the Rheumatic Diseases · 2012 · 72 citations · Full text

Public Health, Infectious Diseases, Internal Medicine +17

Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs

Camille P. Figueiredo, Holger Bang, Jayme Fogagnolo Cobra et al. · Annals of the Rheumatic Diseases · 2016 · 63 citations

Life Sciences, Immunology, Internal Medicine +17